Glutathione is a small molecule made from three amino acids that helps cells manage oxidative stress. Your body makes it from glutamate, cysteine, and glycine, and it is the main antioxidant inside cells. It is marketed for "detox," skin, immune, and energy support - but the strongest claims are about redox biology, not guaranteed clinical results, and cosmetic IV skin-lightening has drawn regulatory safety warnings.
Glutathione is an endogenous thiol tripeptide central to cellular redox buffering, peroxide detoxification, xenobiotic conjugation, and mitochondrial antioxidant defense. Human data support oral and liposomal body-store increases, plus selected clinical-route studies (IV Parkinson pilot, inhaled cystic fibrosis), but protocol-level dosing remains route- and indication-specific.
GSH functions through the GSH/GSSG redox couple, glutathione-peroxidase / peroxiredoxin-linked peroxide handling, glutathione-S-transferase conjugation, NADPH-dependent regeneration, and γ-glutamyl-cycle turnover. IV GSH has a very short plasma half-life (~14 min), so clinical translation depends heavily on delivery route, compartmental uptake, baseline redox deficiency, and whether measured biomarker shifts map to validated outcomes.
Glutathione stands apart from most of this atlas: it is an endogenous tripeptide with genuine human RCT evidence for raising body stores and for several condition-specific uses - stronger footing than the typical "research peptide." But that evidence sits alongside a large unvalidated wellness market. The page keeps the solid redox biology and route-specific trial data separate from broad detox / anti-aging / cosmetic-IV claims, and flags that the real risk is usually route and product quality, not the molecule.
Glutathione's power comes from a single sulfur atom on its cysteine. That "thiol" can grab reactive molecules that would otherwise damage cells, then get recycled back to its fresh form. It also helps the body tag and clear toxins, and it backs up other antioxidants like vitamins C and E.
GSH is a multi-purpose reducing agent. Its reduced thiol donates electrons to neutralize peroxides (via glutathione peroxidase), conjugates electrophiles (via glutathione-S-transferases), and is regenerated from GSSG by glutathione reductase using NADPH. The GSH:GSSG ratio is a core readout of cellular redox tone, and mitochondrial GSH is a particular focus in neurodegenerative models.
GSH operates through the GSH/GSSG couple, GPx/peroxiredoxin-linked peroxide handling, GST conjugation feeding the mercapturic-acid pathway, NADPH-dependent regeneration, and γ-glutamyl-cycle turnover (γ-GT, γ-glutamyl cyclotransferase, 5-oxoprolinase). Because intact GSH is poorly taken up and rapidly cleared, much of supplementation biology is really about supplying precursors and raising compartmental stores.
Glutathione dosing splits cleanly by route - oral supplement, liposomal oral, compounded sterile injectable, inhaled/nebulized, and topical cosmetic - and the evidence and risk differ sharply across them. The tables below are Atlas protocol models, not medical advice; only patterns with human-literature, trial precedent, or clear practice rationale are included, and most broad wellness protocols are Grade D. Working unit: mg.
| Band | Oral / liposomal | Injectable (educational) | Basis / grade |
|---|---|---|---|
| Low | 250 mg/day | 200-600 mg per dose | Oral RCT low arm; conservative injection model - B/D |
| Standard | 500-1000 mg/day | 600-1200 mg per dose | Oral/liposomal human studies; common supervised range - B/D |
| High | >1000 mg/day | >1400 mg (indication-specific) | PD pilot 1400 mg IV 3x/wk; oncology high-dose - B/D |
Injectable bands are educational models, not validated wellness dosing. Glutathione is usually dosed as fixed mg, not validated mg/kg.
| Body weight | Low (250 mg) | Standard (500 mg) | High (1000 mg) | 1000 mg as mg/kg |
|---|---|---|---|---|
| 55 kg | 250 mg | 500 mg | 1000 mg | 18.2 mg/kg |
| 65 kg | 250 mg | 500 mg | 1000 mg | 15.4 mg/kg |
| 75 kg | 250 mg | 500 mg | 1000 mg | 13.3 mg/kg |
| 85 kg | 250 mg | 500 mg | 1000 mg | 11.8 mg/kg |
| 95 kg | 250 mg | 500 mg | 1000 mg | 10.5 mg/kg |
| 105 kg | 250 mg | 500 mg | 1000 mg | 9.5 mg/kg |
Glutathione is dosed as fixed mg; this is not a validated weight-based protocol - the mg/kg column is context only.
| Trigger | Action | Rationale |
|---|---|---|
| GI upset on oral dose | Reduce to prior tolerated dose or split dosing | Oral tolerability is formulation-dependent |
| No change after 4-8 weeks | Confirm adherence/formulation; avoid auto-escalation | Body-store effects may not translate into symptoms |
| Airway irritation (nebulized) | Hold & clinician review | Inhaled route can irritate reactive airways |
| Asthma flare, wheeze, chest tightness | HARD STOP until evaluated | Respiratory safety priority |
| Injection-site reaction | Hold injectable; evaluate sterility/allergy | Sterile & hypersensitivity risks |
| Active chemotherapy | Do not self-stack; oncology only | Antioxidants may interact with cancer-therapy context |
| Pregnancy / breastfeeding | Avoid unless clinician-directed | Insufficient protocol-specific safety |
| Athlete IV >100 mL/12 h | HARD STOP unless TUE/medical | WADA prohibited-method rule |
| Biomarker | Why tracked | Validated for protocol decisions? |
|---|---|---|
| Whole-blood GSH | Direct body-store marker (used in oral studies) | Partially - body-store research, not disease outcomes |
| GSH/GSSG ratio | Redox-state marker | Research-use; not validated for wellness dosing |
| RBC GSH | Cellular glutathione pool | Research-use |
| F2-isoprostanes / 8-OHdG | Oxidative stress / DNA damage | Not validated for protocol decisions |
| ALT/AST, creatinine/eGFR | Hepatic / renal safety context | General safety only |
| FEV1 | Inhaled route / CF context | Condition-specific respiratory endpoint |
Reconstitution arithmetic for injectable models only - not a recommendation to inject, and not for oral/topical routes. Formula: concentration = vial mg / diluent mL; draw mL = target mg / concentration; U-100 units = draw mL x 100; doses = vial mg / target mg.
This calculator handles injectable reconstitution arithmetic only. It is not a recommendation to inject glutathione, and large draws are a practical limit: a U-100 insulin syringe holds at most ~1 mL, so a 600 mg dose at 200 mg/mL (3 mL) needs a standard syringe and supervised administration. Injectable use - especially cosmetic IV skin-lightening - carries sterile-compounding and regulatory-safety concerns. Oral/liposomal is the better-evidenced, lower-risk path for raising body stores.
The main risk is route and product quality, not GSH itself - separate oral/topical (lower risk) from injectable/inhaled (higher risk, supervision).
Injectable GSH depends on 503A/503B compliance, USP/NF status, valid COA, and registered manufacturing - verify before any injectable use.
~14-min IV half-life means systemic exposure is brief; do not model GSH as a long-acting injectable.
NAC / GlyNAC supply cysteine + glycine for endogenous synthesis and may be a more practical body-store strategy than direct GSH.
Cosmetic IV skin-lightening is weakly evidenced and has regulatory warnings - not a validated or approved use.
Do not self-stack high-dose GSH during active cancer therapy; antioxidant-chemotherapy interactions require oncology oversight.
Glutathione stacks fall into two camps: redox-network pairings (vitamin C, ALA, NAC) that are mostly mechanistic or practice-pattern, and one combination with real specialized evidence - cisplatin-neurotoxicity mitigation, which must stay oncologist-directed. The most useful "stack" is often a precursor strategy (NAC/GlyNAC), since supplying cysteine and glycine drives endogenous synthesis.
Do not self-administer or stack high-dose glutathione during active cancer therapy, chemotherapy, radiation, or immunotherapy without oncology approval. The cisplatin-neurotoxicity literature is specialized and cannot be generalized to wellness use - antioxidants may help or interfere depending on the regimen and tumor context. For raising body stores, the precursor route (NAC/GlyNAC) is mechanistically sound and lower-risk than gray-market injectable GSH.
As an endogenous molecule, glutathione is generally well tolerated by mouth, and oral/liposomal human studies report good tolerability. The meaningful safety story is route- and product-driven: inhaled GSH carries bronchospasm / airway-irritation risk, IV use depends on sterile-compounding quality and triggers the WADA IV-volume rule, and cosmetic IV skin-lightening has explicit regulatory warnings. Active cancer therapy is a hard-stop without oncology oversight.
| Condition | Concern | Severity |
|---|---|---|
| Active malignancy / cancer treatment | Antioxidant interaction; oncology context required | High |
| Asthma / reactive airway disease (inhaled) | Nebulized route may irritate airways | High (inhaled) |
| Injection outside sterile clinical setting | Contamination / infection risk | High |
| Cosmetic skin-lightening injection | Weak evidence + regulatory warnings | High |
| Competitive athlete (IV >100 mL/12 h) | WADA IV-volume rule | High (IV) |
| Pregnancy / breastfeeding | Insufficient protocol-specific data | High caution |
| Pediatric use | Limited protocol evidence outside specific clinical contexts | High caution |
| Severe liver / kidney disease | Altered redox/metabolic context; medication complexity | Moderate-High |
| Sulfur / thiol sensitivity history | Possible intolerance | Moderate |
| Concurrent chemotherapy | Benefit/risk depends on regimen | Oncology-only |
GI tolerance and symptoms; optional whole-blood GSH for body-store research tracking.
BP, infusion reaction, asthma history, renal/hepatic context, medication interactions, and sterile-quality verification.
FEV1, cough, bronchospasm, oxygenation, airway reactivity - respiratory-clinician oversight.
Irritation, dermatitis, pigment changes, and photosensitivity practices.
Any use during cancer therapy must be oncologist-directed - hard stop for self-administration.
IV infusions >100 mL/12 h are prohibited without a TUE/medical exception - independent of GSH itself.
Glutathione's evidence is genuinely stronger than most "research peptides": moderate human support for raising body stores with oral/liposomal supplementation, and moderate but indication-specific support for inhaled CF, IV Parkinson, and cisplatin-adjunct use. It is weak for broad wellness, anti-aging, detox, and cosmetic IV skin-lightening. What is missing: large disease-specific RCTs, validated biomarker-guided dosing, standardized injectable protocols, and head-to-head trials against precursor strategies (NAC/glycine/cysteine).
A randomized, double-blind, placebo-controlled trial (n=54) of oral glutathione at 250 or 1000 mg/day for 6 months increased GSH stores in blood compartments - the cleanest evidence that oral GSH can raise body stores.
Oral liposomal glutathione elevated body GSH stores and markers of immune function in a human pilot at 500 and 1000 mg/day - promising but formulation-specific and small.
A randomized, double-blind pilot (n=20) of 1400 mg IV three times weekly for 4 weeks was safe and tolerated with a preliminary symptom signal; a systematic review frames GSH's potential and the need for larger trials.
A randomized, double-blind, placebo-controlled trial of inhaled glutathione in CF patients reported modest/mixed respiratory outcomes - a real but condition-specific signal, not a wellness protocol.
A randomized double-blind trial found reduced glutathione lessened cisplatin-related neurotoxicity in advanced gastric cancer, and a split-face study of 2% topical oxidized glutathione improved melanin index / skin condition.
High-dose IV GSH showed a plasma half-life of ~14 min, consistent with PK work describing a short half-life; reviews detail its pharmacological role and clinical-use implications, built on the two-step ATP-dependent synthesis via GCL and glutathione synthetase.
Overall evidence is moderate for raising glutathione body stores with oral/liposomal supplementation (oral RCT, liposomal pilot), and moderate but indication-specific for inhaled CF, IV Parkinson, and cisplatin-adjunct use (PD pilot, cisplatin RCT). It is weak for broad wellness, anti-aging, detox, and cosmetic IV skin-lightening. The key gaps are large disease-specific RCTs, validated biomarker-guided dosing, standardized injectable protocols, long-term route-specific safety, and head-to-head trials against precursor strategies (NAC / glycine / cysteine). Glutathione earns its place as a foundational redox tripeptide with real - but bounded - human evidence.
| Study / source | Design | Route / dose | Outcome | Grade |
|---|---|---|---|---|
| Richie 2015 | RCT, n=54 | Oral 250 or 1000 mg/d x 6 mo | ↑ blood GSH stores | B |
| Sinha 2018 | Human pilot | Liposomal 500/1000 mg/d | ↑ GSH stores & immune markers | B |
| Hauser 2009 | RCT pilot, n=20 | IV 1400 mg 3x/wk x 4 wk (PD) | Safe/tolerated; preliminary signal | B |
| Inhaled CF trial | RCT, placebo-controlled | Nebulized GSH | Modest/mixed respiratory outcomes | B |
| Cabassi/cisplatin trials | RCT (oncology) | IV GSH + cisplatin | Reduced neurotoxicity signals | B |
| Topical GSSG | Split-face, n=30 | 2% topical GSSG | ↑ melanin index / skin condition | B |
| IV PK study | Human PK | High-dose IV | t½ ~14 min | B |
| GSH synthesis / GST | Biochemical | - | GCL + GS synthesis; GST conjugation | P |
The most useful comparison is GSH versus the molecules used to raise or deliver it. Direct GSH is the active tripeptide but is poorly absorbed and rapidly cleared; NAC is an approved drug (for other indications) that donates cysteine; GlyNAC supplies both rate-limiting precursors; and S-acetyl glutathione is a stability-modified delivery form with thinner evidence.
| Feature | Glutathione (GSH) | NAC | GlyNAC | S-acetyl glutathione |
|---|---|---|---|---|
| Role | The active tripeptide | Cysteine donor / mucolytic | Glycine + cysteine precursor load | Modified GSH delivery |
| Mechanism class | Endogenous thiol tripeptide | Cysteine donor / antidote | Dual precursor strategy | GSH derivative / prodrug-like |
| Evidence tier | Human RCTs for several endpoints | Strong approved-drug evidence (specific uses) | Emerging human aging/metabolic studies | Less human evidence than GSH/NAC |
| Route | Oral, IV, inhaled, topical | Oral, IV, inhaled | Oral | Oral |
| Regulatory status | Supplement/compounding; no broad wellness IV approval | FDA-approved (acetaminophen toxicity, etc.) | Supplement / research | Supplement / research |
| Key caution | Route/product quality; cosmetic IV warnings | GI/respiratory effects; not interchangeable with GSH | Emerging evidence; not yet definitive | Stability/uptake claims need verification |